Tempest Therapeutics Management

Management criteria checks 0/4

Tempest Therapeutics' CEO is Matt Angel, appointed in Feb 2026, has a tenure of less than a year. directly owns 32.67% of the company’s shares, worth $4.72M. The average tenure of the management team and the board of directors is 0.4 years and 0.4 years respectively.

Key information

Matt Angel

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	32.7%
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

Seeking Alpha • Aug 15

Tempest Therapeutics GAAP EPS of -$0.79

Tempest Therapeutics press release (NASDAQ:TPST): Q2 GAAP EPS of -$0.79. Tempest ended the second quarter of 2022 with $51.6M in cash and cash equivalents, compared to $51.8M at Dec. 31, 2021. The decrease was primarily due to cash used in operations of $15.5M offset by proceeds from the PIPE financing of $14.5M (net of issuance costs).

Seeking Alpha • Jan 04

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Tempest Therapeutics is a clinical-stage biotech developing small molecule therapy to treat cancer. CEO Stephen Brady joined us to discuss clinical studies, partnering with Roche and how he thinks about licensing and M&A. Allowing the immune system to do its job; biotech investing trends.

CEO

Matt Angel (45 yo)

less than a year

Tenure

Dr. Matthew Angel, Ph D., also known as Matt, is President, CEO & Director at Tempest Therapeutics, Inc. from February 03, 2026. He served as Chief Executive Officer at Eterna Therapeutics Inc.(Ernexa Ther...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Angel	President	less than a year	no data	32.67% $ 4.7m
Justin Trojanowski	VP of Finance	3.8yrs	no data	no data
Andrew Fang	Head of Business Development	less than a year	no data	no data

0.4yrs

Average Tenure

Experienced Management: TPST's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Matthew Angel	President	less than a year	no data	32.67% $ 4.7m
Andrew Pardoll	Member of Advisory Board	no data	no data	no data
Raymond DuBois	Member of Advisory Board	no data	no data	no data
Petpiboon Prasit	Member of Advisory Board	no data	no data	no data
Benjamin Cravatt	Member of Advisory Board	7.2yrs	no data	no data
William Richey	Independent Director	less than a year	no data	0.014% $ 2.0k
John Yee	Independent Director	less than a year	no data	no data
Jason J. Luke	Member of Advisory Board	no data	no data	no data
Toni Choueiri	Member of Advisory Board	no data	no data	no data
Russell Vance	Member of Advisory Board	4.8yrs	no data	no data

0.4yrs

Average Tenure

56yo

Average Age

Experienced Board: TPST's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/10 21:49
End of Day Share Price	2026/07/10 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tempest Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joseph Pantginis	H.C. Wainwright & Co.
Maurice Raycroft	Jefferies LLC
Aydin Huseynov	Ladenburg Thalmann & Company

Tempest Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Tempest Therapeutics, Inc. Announces Directorate Appointments Effective June 4, 2026

Tempest Therapeutics, Inc. Appoints Andrew Fang, Ph.D. as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics, Inc. Announces Board and Executive Changes Effective February 3, 2026

Tempest Therapeutics, Inc., Annual General Meeting, Dec 31, 2025

Insufficient new directors

CEO, President & Director recently bought US$74k worth of stock

Recent updates

Tempest Therapeutics, Inc. Announces Directorate Appointments Effective June 4, 2026

Tempest Therapeutics, Inc. Receives Deficiency Letter from Nasdaq

Tempest Therapeutics, Inc. Appoints Andrew Fang, Ph.D. as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors

New minor risk - Share price stability

Tempest Therapeutics, Inc. Announces Interim Results from Ongoing RedeEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Therapeutics, Inc. Announces Board and Executive Changes Effective February 3, 2026

Tempest Therapeutics Receives Notice of Non -Compliance with Nasdaq Listing Rules

Tempest Therapeutics, Inc., Annual General Meeting, Dec 31, 2025

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.249315 million.

New major risk - Revenue and earnings growth

Tempest Therapeutics, Inc. Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.618416 million.

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

New minor risk - Share price stability

Price target decreased by 51% to US$9.50

Fda Study May Proceed Notice Received for Phase 2 Trial of Tpst-1495 for the Treatment of Familial Adenomatous Polyposis (Fap)

Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation (FTD) to Amezalpat (TPST-1120)

Tempest Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Financial position

Tempest Therapeutics, Inc. Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Insufficient new directors

Tempest Announces Successful End-Of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

New major risk - Share price stability

New major risk - Financial position

CEO, President & Director recently bought US$74k worth of stock

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

Tempest Unveils New Survival Data for Amezalpat in Randomized First-Line Hcc Study Demonstrating Six-Month Improvement over Control Arm

New major risk - Share price stability

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting

Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Price target increased by 26% to US$19.67

Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development

High number of new and inexperienced directors

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Announces Executive Changes

Price target decreased by 18% to US$15.67

New major risk - Market cap size

Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Price target increased by 16% to US$19.00

No independent directors

Tempest Therapeutics, Inc. Announces Executive Changes

Tempest Therapeutics GAAP EPS of -$0.79

Tempest Therapeutics Inc. Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 17, 2022